MDMB-FUBICA, a synthetic cannabinoid, is a potent agonist of the cannabinoid receptors with psychoactive properties. MDMB-FUBICA can be used in electronic cigarette.

MDMB-FUB7AICA is structurally similar to known synthetic cannabinoids.

MDA77 is a CB2 inverse agonist with an EC50 of 5.82 nM, showing selectivity for human CB2 and no activity on CB1.

MDA7 is the selective agonist for cannabinoid receptor 2 with EC50 of 128 nM and 67.4 nM in human CB2 receptor and rat CB2 receptor. MDA7 exhibits good affinity to human CB2 receptor and rat CB2 receptor with Ki of 422 nM and 238 nM. MDA7 exhibits analgesic activity in rats models.

iso-Hexahydrocannabinol is structurally similar to known phytocannabinoids.

Hexocannabitriol is structurally similar to known phytocannabinoids.

FDU-PB-22 is a new synthetic cannabinoid that is rapidly metabolized in HLM, with a half-life of 12.4 minutes.

exo-THCP (exo-Tetrahydrocannabiphorol) is structurally similar to known phytocannabinoids.

exo-Tetrahydrocannabivarin (Compound 12) is a Δ9,11-THC analogue. exo-Tetrahydrocannabivarin weakly binds to cannabinoid receptors (CB) (IC50: 1.4 μM). exo-Tetrahydrocannabivarin is active on both motor and analgesic aspects in mice.

Dehydrocannabifuran (6-Methyl-9-isopropenyl-3-pentyldibenzofuran-1-ol) is a phytocannabinoid derivative.

CHM-FUBIATA is structurally similar to known synthetic cannabinoids.

CH-FUBIATA is structurally similar to known synthetic cannabinoids.

CE-178253 benzenesulfonate is a CB1 antagonist with central nervous system activity.

Carmagerol is a phytocannabinoid metabolite.

Cannabiorcol (Cannabinol C1) is structurally similar to known phytocannabinoids.

Cannabinol methyl ether is a phytocannabinoid.

Cannabinol ethyl (CBN-C2) is structurally similar to known phytocannabinoids.

Cannabinol acetate (Acetylcannabinol) is structurally similar to known phytocannabinoids.

Cannabigerorcinic acid is structurally similar to known phytocannabinoids.

Cannabigerorcin is a phenolic compound found in cannabis plants, featuring a diphenol backbone and a terpene side chain. By reacting with radiolabeled methylmagnesium carbonate (MMC), its carboxyl group can be 14C-labeled. Radiolabeled Cannabigerorcin is widely used in research on cannabinoid biosynthesis pathways and metabolic processes.

Cannabigerophorol (CBGP) is structurally similar to known synthetic cannabinoids.

Cannabigerolic acid monomethyl ether is structurally similar to known phytocannabinoids.

Cannabigerol diacetate is structurally similar to known phytocannabinoids.

Cannabigerobutolic acid (CBGBA) is structurally similar to known phytocannabinoids.

Cannabidivarin diacetateis structurally similar to known phytocannabinoids.

Cannabidiol-C8 is structurally similar to known phytocannabinoids.

Cannabidiol monomethyl ether is a phytocannabinoid.

Cannabidihexol is a phytocannabinoid with analgesic activity in mice.

BNS808 is an orally active and selective cannabinoid-1 receptor (CB1R) antagonist (IC50 = 0.8 nM) with notable CB2R selectivity and minimal brain penetration. BNS808 is studied in research on obesity and its associated metabolic complications, such as metabolic dysfunctional-associated steatotic liver disease (MASLD). BNS808 has reduced free drug availability for CNS entry, enhancing safety and minimizing drug-drug interactions through high plasma binding.

BB-223-carboxyindole metabolite (B-223-Carboxyindolemetabolite) is a metabolite of BB-22. BB-22 is an analog of cannabinoid.